Premium
Biodegradable implants for sustained drug release: Manufacturing considerations, drug stability, and drug release
Author(s) -
Kompella U.B.
Publication year - 2017
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2017.02143
Subject(s) - drug , plga , implant , drug delivery , dexamethasone , dosage form , controlled release , pharmacology , biomedical engineering , drug carrier , medicine , materials science , surgery , nanoparticle , nanotechnology
Summary Poly(D,L‐lactide‐co‐glycolide) ( PLGA ) is a biodegradable polymer used in preparing sustained release dosage forms including implants, microparticles, and nanoparticles. Indeed, an intravitreally injectable PLGA implant loaded with dexamethasone, an anti‐inflammatory corticosteroid, has been approved for treating retinal vein occlusion, posterior segment uveitis, and diabetic macular edema. The purpose of this study was to determine the influence of implant manufacturing method on release of dexamethasone from PLGA implants. Melt compression and hot‐melt extrusion were the two methods employed for implant manufacturing. Drug release from implants was assessed over 10 weeks in phosphate buffered saline ( PBS , pH 7.4) maintained at 37 degrees Centigrade. Drug stability in PBS was assessed under the same conditions. The results indicated degradation of dexamethasone to over 10 products in PBS . Drug amounts in release medium were corrected for drug degradation, in order to estimate actual drug release. The two manufacturing methods resulted in different drug release profiles.